|
ESI Special
Topics: January 2007
Citing URL: http://esi-topics.com/hiv-aids/interviews/DouglasRichman.html |
|
An INTERVIEW with Dr. Douglas Richman
|
|
 his
month, Special Topics has a brief conversation with Dr.
Douglas Richman about his highly cited research on HIV/AIDS.
According to our analysis of this field over the past decade,
Dr. Richman’s work ranks at #1, with 131 papers cited a
total of 12,444 times, with four of these papers making our
top 20 listings. In
Essential
Science Indicators ,
Dr. Richman’s work can be found in the fields of Clinical
Medicine, Immunology, and Microbiology.
Dr. Richman
received his M.D. from Stanford University. He is currently
Professor of Pathology and Medicine at the University of
California, San Diego, where he is also Director of the Center
for AIDS Research as well as the Florence Seeley Riford Chair
in AIDS Research. He is also affiliated with the VA San Diego
Healthcare System, where he is the Director of the Research
Center for AIDS and HIV Infection. In addition to these
positions, Dr. Richman is also a member of the NIH AIDS
Vaccine Research Committee.
|
 Your
most-cited paper is the 1997 NEJM paper on treatment of HIV
with indinavir, zidovudine, and lamivudine. How effective did this
treatment prove to be? Is it still a viable therapeutic option for
today?
|
“I feel an effective HIV vaccine is one of the most important objectives of medical science.”
|
|
This paper generated the HIV treatment paradigm of suppression of
plasma HIV RNA below the limits of detection. This combination
regimen could suppress HIV replication in most patients to levels
below the limits of detection, while none of the individual
components could do so. Although this particular regimen is no
longer used, the principle remains the standard-of-practice.
You
are a part of the International AIDS Society-USA Panel. How often are
antiretroviral therapy recommendations reviewed and revised? How
difficult is it to come up with a consensus?
The panel assembles for an update every three years or so when we
feel there is enough new information to merit an update. The latest
has been completed and was published in August 2006 (Hammer SM, et
al., "Treatment for adult HIV infection - 2006
recommendations of the International AIDS Society-USA panel," JAMA
296[7]: 827-843, 16 August 2006).
It
has been 25 years since the first paper describing the clinical
symptoms of HIV/AIDS was published. What’s your take on the progress
that has been made?
The progress in HIV therapy has been a truly remarkable testimony
to medical accomplishment. With access to care and adherence,
patients with a formerly fatal affliction can now for the most part
prevent HIV infection from impacting their morbidity and mortality.
The greatest unmet needs for management of HIV? For treatment we
have no insights on how to purge the latent reservoir and cure the
infection. For prevention we are a long way off from an effective
vaccine. I feel an effective HIV vaccine is one of the most
important objectives of medical science.
Douglas D. Richman, M.D.
VA San Diego Healthcare System
and
Professor of Pathology and Medicine
University of California San Diego
Director, Center for AIDS Research
Florence Seeley Riford Chair in AIDS Research
La Jolla, CA, USA
| Dr. Douglas Richman's
most-cited paper with 1,016 cites to date: |
|
Gulick RM, et
al., "Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy,"
N. Engl. J. Med. 337(11): 734-9, 11 September 1997.
Source:
Essential Science Indicators |
|
| Related
Links:
|
|
Dr.
Douglas Richman
is featured in ISIHighlyCited.com |
|
|
ESI Special
Topics: January 2007
Citing URL: http://esi-topics.com/hiv-aids/interviews/DouglasRichman.html
|
|
|
